BND-22 (SAR444881) is a first-in-class humanized IgG4 antagonist antibody targeting ILT2 (LILRB1), an inhibitory receptor expressed on both innate and adaptive immune cells, including macrophages, NK cells, and CD8⁺ T cells. By blocking the interaction between ILT2 and its ligand HLA-G, BND-22 is designed to restore anti-tumor immunity across multiple immune compartments.

HLA-G is an immunosuppressive molecule expressed by a broad range of solid tumors and is associated with immune evasion and poor clinical outcomes. By disrupting the ILT2–HLA-G axis, BND-22 reverses inhibitory “do not eat me” signaling in macrophages and enhances the cytotoxic activity of NK cells and CD8⁺ T cells, resulting in coordinated activation of both the innate and adaptive immune systems.

BND-22 demonstrated a favorable safety profile and encouraging anti-tumor activity as both monotherapy and in combination with pembrolizumab and cetuximab. Clinical activity was particularly notable in patients with microsatellite-stable colorectal cancer (MSS-CRC) and cholangiocarcinoma, including patients who had relapsed following prior cetuximab treatment and those with liver metastases. Pharmacodynamic analyses showed dose-dependent activation of ILT2-expressing T cells, NK cells, and monocytes.

BND-22 is currently being evaluated in an ongoing Phase 2 study in combination with anti–PD-1, with the goal of identifying predictive biomarkers of response and refining patient selection strategies for future registrational studies.


See Clinical Trials

Biond retains worldwide development and commercialization rights to BND-22. The program represents a differentiated immuno-oncology approach designed to overcome tumor immune escape by targeting a central inhibitory pathway shared across multiple immune cell types.